SI9720044B - Imunološka metoda detekcije protiteles proti tkivni transglutaminazi (tTG), uporaba tkivne transglutaminaze v diagnosticiranju in nadziranju terapije in oralna farmacevtska zmes, ki vsebuje tkivno transglutaminazo - Google Patents

Imunološka metoda detekcije protiteles proti tkivni transglutaminazi (tTG), uporaba tkivne transglutaminaze v diagnosticiranju in nadziranju terapije in oralna farmacevtska zmes, ki vsebuje tkivno transglutaminazo Download PDF

Info

Publication number
SI9720044B
SI9720044B SI9720044A SI9720044A SI9720044B SI 9720044 B SI9720044 B SI 9720044B SI 9720044 A SI9720044 A SI 9720044A SI 9720044 A SI9720044 A SI 9720044A SI 9720044 B SI9720044 B SI 9720044B
Authority
SI
Slovenia
Prior art keywords
ttg
tissue
diagnosis
therapy control
immunologically reactive
Prior art date
Application number
SI9720044A
Other languages
English (en)
Other versions
SI9720044A (sl
Inventor
Detlef Schuppan
Walburga Dieterich
Tobias Ehnis
Original Assignee
Detlef Schuppan
Walburga Dieterich
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7801172&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI9720044(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Detlef Schuppan, Walburga Dieterich filed Critical Detlef Schuppan
Publication of SI9720044A publication Critical patent/SI9720044A/sl
Publication of SI9720044B publication Critical patent/SI9720044B/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1025—Acyltransferases (2.3)
    • C12N9/104—Aminoacyltransferases (2.3.2)
    • C12N9/1044—Protein-glutamine gamma-glutamyltransferase (2.3.2.13), i.e. transglutaminase or factor XIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Rheumatology (AREA)
  • Wood Science & Technology (AREA)
  • Rehabilitation Therapy (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)

Claims (9)

  1. Sl 9720044 PATENTNI ZAHTEVKI METODA IMUNOLOŠKE DETEKCIJE PROTITELES PROTI TKIVNI TRANSGLUTAMINAZI (tTG), UPORABA tTG V DIAGNOSTICIRANJU IN NADZIRANJU TERAPIJE IN ORALNO FARMACEVTSKO SREDSTVO, KI VSEBUJE TKIVNO tTG 1. Metoda za diagnozo ali nadzor terapije ceiiakije, označena s tem, da so protitelesa proti tkivni transglutaminazi (tTG) iz telesnih tekočin detektirana z imunološko reakcijo s tkivno transglutaminazo (tTG), njenimi imunološko reaktivnimi sekvencami ali analogi, pri čemer imunološka reakcija ni izvedena z odščipkom živalskega ali človeškega tkiva.
  2. 2. Metoda po zahtevku 1, označena s tem, da so detektirana človeška IgA in/ali IgG protitelesa.
  3. 3. Metoda po zahtevku 1 ali 2, označena s tem, da je tTG človeškega, živalskega, sintetičnega ali rekombinantnega izvora.
  4. 4. Metoda po enem izmed zahtevkov 1 do 3, označena s tem, da je detekcija izvedena z uporabo poznanih imunoloških testov, prednostno z direktno in indirektno vezavo enega od reaktantov na označevalne snovi, ki se dajo dobro detektirati.
  5. 5. Metoda po zahtevku 4, označena s tem, da je detekcija izvedena na trdni fazi
  6. 6. Metoda po zahtevku 4, označena s tem, da je detekcija izvedena z uporabo ELISA, RIA ali imunofluorescentnega imunološkega testa.
  7. 7. Uporaba tTG, njenih imunološko reaktivnih sekvenc ali analogov v diagnosticiranju ali nadzoru terapije ceiiakije, pri čemer ni uporabljen odščipek živalskega ali človeškega tkiva.
  8. 8. Oralno farmacevtsko sredstvo, ki vsebuje tTG, njene imunološko reaktivne sekvence ali analoge in po potrebi farmacevtsko prenesljive dodatke za zdravljenje ceiiakije.
  9. 9. Uporaba tTG, njenih imunološko reaktivnih sekvenc ali analogov za pripravo oralnih farmacevtskih sredstev za zdravljenje ceiiakije.
SI9720044A 1996-07-18 1997-07-14 Imunološka metoda detekcije protiteles proti tkivni transglutaminazi (tTG), uporaba tkivne transglutaminaze v diagnosticiranju in nadziranju terapije in oralna farmacevtska zmes, ki vsebuje tkivno transglutaminazo SI9720044B (sl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19630557A DE19630557C2 (de) 1996-07-18 1996-07-18 Verfahren zum Nachweis von Antikörpern aus Körperflüssigkeiten durch eine Immunreaktion mit Gewebe-Transglutaminase (tTG) sowie die Verwendung von tTG in Diagnose und Therapie
PCT/EP1997/003740 WO1998003872A2 (de) 1996-07-18 1997-07-14 IMMUNOLOGISCHES NACHWEISVERFAHREN VON ANTIKÖRPERN, DIE GEGEN GEWEBE-TRANSGLUTAMINASE (tTG) GERICHTET SIND, VERWENDUNG VON tTG ZUR DIAGNOSE UND THERAPIEKONTROLLE SOWIE ORALES PHARMAZEUTISCHES MITTEL ENTHALTEND tTG

Publications (2)

Publication Number Publication Date
SI9720044A SI9720044A (sl) 1999-08-31
SI9720044B true SI9720044B (sl) 2003-02-28

Family

ID=7801172

Family Applications (1)

Application Number Title Priority Date Filing Date
SI9720044A SI9720044B (sl) 1996-07-18 1997-07-14 Imunološka metoda detekcije protiteles proti tkivni transglutaminazi (tTG), uporaba tkivne transglutaminaze v diagnosticiranju in nadziranju terapije in oralna farmacevtska zmes, ki vsebuje tkivno transglutaminazo

Country Status (22)

Country Link
US (2) US6319726B1 (sl)
EP (1) EP0912898B1 (sl)
CN (1) CN1138146C (sl)
AT (1) ATE210296T1 (sl)
AU (1) AU718797B2 (sl)
BR (1) BR9710500B1 (sl)
CA (1) CA2260769C (sl)
CZ (1) CZ291662B6 (sl)
DE (2) DE19630557C2 (sl)
DK (1) DK0912898T3 (sl)
ES (1) ES2131038T3 (sl)
GR (1) GR990300020T1 (sl)
HK (1) HK1021025A1 (sl)
HU (1) HU228479B1 (sl)
IL (1) IL128042A (sl)
NO (1) NO321466B1 (sl)
NZ (1) NZ333744A (sl)
PL (1) PL189091B1 (sl)
PT (1) PT912898E (sl)
SI (1) SI9720044B (sl)
SK (1) SK284410B6 (sl)
WO (1) WO1998003872A2 (sl)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3596199A (en) * 1998-05-06 1999-11-23 Kobenhavns Universitet Treatment of celiac disease
WO2001001133A2 (en) * 1999-06-28 2001-01-04 Immundiagnostik Ag Diagnosis of gluten sensitive enteropathy and other autoimmunopathies
US6703208B1 (en) 1999-10-20 2004-03-09 Immco Diagnostics Immunological assay for detection of antibodies in celiac disease
AU1966201A (en) * 1999-10-20 2001-04-30 Immco Diagnostics Immunological assay for detection of antibodies in celiac disease
CU22968A1 (es) * 2000-06-07 2004-07-14 Ct Ingenieria Genetica Biotech Procedimiento para la detección de anticuerpos anti transglutaminasa con utilidad en el diagnóstico de la enfermedad celíaca
GB0103024D0 (en) * 2001-02-07 2001-03-21 Rsr Ltd Assay for Autoantibodies to tissue transglutaminase
FI20010868A0 (fi) 2001-04-25 2001-04-25 Markku Maeki Menetelmä ja välineet gluteenin indusoimien tautien havaitsemiseksi
KR100488131B1 (ko) * 2001-07-07 2005-05-06 (주)푸드바이오테크 알레르기 진단용 단백질 칩과 알레르기 유발원의 검출방법 및 알레르기 유발 항체의 검출 방법
GB0117870D0 (en) 2001-07-21 2001-09-12 Univ Nottingham Trent Method of diagnosis and kit of parts therefor
US7320788B2 (en) * 2002-02-14 2008-01-22 The Board Of Trustees Of The Leland Stanford Junior University Enzyme treatment of foodstuffs for Celiac Sprue
US8143210B2 (en) 2002-02-14 2012-03-27 The Board Of Trustees Of The Leland Stanford Junior University Enzyme treatment of foodstuffs for celiac sprue
DE60336754D1 (de) * 2002-02-14 2011-05-26 Univ R Enzymbehandlung von nahrungsmitteln für zöliakie-sprue
US7202216B2 (en) * 2002-05-14 2007-04-10 The Board Of Trustees Of The Leland Stanford Junior University Drug therapy for celiac sprue
CA2487247A1 (en) * 2002-05-14 2003-11-27 The Board Of Trustees Of The Leland Stanford Junior University Drug therapy for celiac sprue
US7265093B2 (en) * 2002-05-14 2007-09-04 The Board Of Trustees Of The Leland Stanford Junior University Drug therapy for Celiac Sprue
US7462688B2 (en) * 2002-05-14 2008-12-09 The Board Of Trustees Of The Leland Stanford Junior University Peptides for diagnostic and therapeutic methods for celiac sprue
EP1563300B1 (en) 2002-11-20 2012-04-18 The Board Of Trustees Of The Leland Stanford Junior University Diagnostic method for celiac sprue
US7579313B2 (en) 2003-11-18 2009-08-25 The Board Of Trustees Of The Leland Stanford Junior University Transglutaminase inhibitors and methods of use thereof
US7628985B2 (en) * 2004-04-26 2009-12-08 The Board Of Regents Of The Leland Stanford Junior University Therapeutic enzyme formulations and uses thereof in celiac sprue and/or dermatitis herpetoformis
US7563864B2 (en) * 2004-04-26 2009-07-21 Celiac Sprue Research Foundation Prolyl endopeptidase mediated destruction of T cell epitopes in whole gluten
US7534426B2 (en) * 2004-04-26 2009-05-19 The Board Of Trustees Of The Leland Stanford Junior University Glutenase enzyme assays
US20080038760A1 (en) * 2004-06-08 2008-02-14 Method For Decting Anti-Transglutaminase Antibodies Method for Detecting Anti-Transglutaminase Antibodies
US20090305303A1 (en) * 2006-07-25 2009-12-10 Cecile Besson Duvanel immunochromatography device for the diagnosis of diseases in a sample
ES2369544T3 (es) * 2007-01-26 2011-12-01 Ga Generic Assays Gmbh Procedimiento para la detección de anticuerpos en fluidos corporales mediante una reacción inmunitaria con glicoproteína 2 (gp2) de gránulos de zimogeno del páncreas para el diagnóstico diferencial de enfermedades inflamatorias del intestino y pancreatitis crónica.
US8778338B2 (en) * 2007-03-16 2014-07-15 The Board Of Trustees Of The Leland Stanford Junior University Combination enzyme therapy for digestion of dietary gluten
ATE511651T1 (de) 2007-04-06 2011-06-15 Zedira Gmbh Transglutaminase 6 als diagnostischer indikator für autoimmunerkrankungen
HU0900199D0 (en) * 2009-04-01 2009-06-29 Debreceni Egyetem Diagnosis of gluten-induced autoimmune diseases
FR2949782B1 (fr) 2009-09-04 2015-10-16 Isp Investments Inc Peptide activateur de la transglutaminase et composition cosmetique ou pharmaceutique le contenant.
JP6012767B2 (ja) 2012-02-07 2016-10-25 ヴィブラント ホールディングス リミテッド ライアビリティ カンパニー 基板、ペプチドアレイ、および方法
PT2839290T (pt) 2012-04-17 2019-06-12 Aeneas Gmbh & Co Kg Processo para diagnóstico pré-sintomático de doença celíaca e sensibilidade ao glúten
DE102012007510A1 (de) 2012-04-17 2013-10-17 Aesku.Diagnostics GmbH & Co. KG Verfahren zur Präsymptomatischen Diagnostik von Zöliakie und Glutensensitivität
US10006909B2 (en) 2012-09-28 2018-06-26 Vibrant Holdings, Llc Methods, systems, and arrays for biomolecular analysis
US10286376B2 (en) 2012-11-14 2019-05-14 Vibrant Holdings, Llc Substrates, systems, and methods for array synthesis and biomolecular analysis
JP5981667B2 (ja) 2013-02-15 2016-08-31 ヴィブラント ホールディングス リミテッド ライアビリティ カンパニー 増幅された電気化学発光検出のための方法および組成物
CN104090102B (zh) * 2014-06-13 2016-08-17 江南大学 冷冻鱼糜中微生物谷氨酰胺转胺酶elisa检测方法
AU2015314934A1 (en) 2014-09-10 2017-04-20 Vibrant Holdings, Llc Peptide microarrays and novel biomarkers for celiac disease
US10538808B2 (en) 2017-05-26 2020-01-21 Vibrant Holdings, Llc Photoactive compounds and methods for biomolecule detection and sequencing
CN110055235A (zh) * 2019-05-14 2019-07-26 深圳市亚辉龙生物科技股份有限公司 用于转谷氨酰胺酶抗体检测的抗原及其制备方法、试剂盒及检测方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL155894B1 (en) * 1987-12-23 1992-01-31 Przed Zagraniczne W Polsce Pla Test for assessing gluten-dependent enteropathies
DE3829524A1 (de) * 1988-08-31 1990-03-01 Behringwerke Ag Verwendung von transglutaminasen als immunsuppressiva
DE19520480C2 (de) 1995-06-03 1997-04-30 Univ Leipzig Immunochemisches Testmaterial und Enzymimmunoassay zur Diagnostik von Zöliakie und verwandten Eiweißintoleranzen
US5716794A (en) * 1996-03-29 1998-02-10 Xybernaut Corporation Celiac antigen

Also Published As

Publication number Publication date
SK6799A3 (en) 2000-05-16
NO990190L (no) 1999-03-15
DE19630557C2 (de) 1998-07-02
EP0912898B1 (de) 2001-12-05
ES2131038T1 (es) 1999-07-16
AU718797B2 (en) 2000-04-20
US20020076834A1 (en) 2002-06-20
NZ333744A (en) 2000-03-27
DK0912898T3 (da) 2002-04-08
WO1998003872A2 (de) 1998-01-29
CA2260769A1 (en) 1998-01-29
BR9710500A (pt) 2000-01-18
IL128042A0 (en) 1999-11-30
CN1138146C (zh) 2004-02-11
DE59705683D1 (de) 2002-01-17
HU228479B1 (en) 2013-03-28
CA2260769C (en) 2005-09-06
HK1021025A1 (en) 2000-05-26
SK284410B6 (sk) 2005-03-04
HUP0202779A3 (en) 2009-07-28
BR9710500B1 (pt) 2009-05-05
IL128042A (en) 2007-06-17
CZ291662B6 (cs) 2003-04-16
ATE210296T1 (de) 2001-12-15
HUP0202779A2 (hu) 2002-12-28
DE19630557A1 (de) 1998-01-29
PL189091B1 (pl) 2005-06-30
PT912898E (pt) 2002-05-31
GR990300020T1 (en) 1999-06-30
CZ11799A3 (cs) 1999-07-14
NO321466B1 (no) 2006-05-15
WO1998003872A3 (de) 1998-03-12
SI9720044A (sl) 1999-08-31
PL331203A1 (en) 1999-07-05
US6319726B1 (en) 2001-11-20
EP0912898A2 (de) 1999-05-06
ES2131038T3 (es) 2002-09-01
NO990190D0 (no) 1999-01-15
AU4201197A (en) 1998-02-10
CN1225723A (zh) 1999-08-11

Similar Documents

Publication Publication Date Title
SI9720044B (sl) Imunološka metoda detekcije protiteles proti tkivni transglutaminazi (tTG), uporaba tkivne transglutaminaze v diagnosticiranju in nadziranju terapije in oralna farmacevtska zmes, ki vsebuje tkivno transglutaminazo
Charriere et al. Reactions to a bovine collagen implant: Clinical and immunologic study in 705 patients
Jackson et al. Dynamic characteristics of gastrin release
KR910002897A (ko) 에리트로포이에틴(epo)펩타이드 및 이에 대한 항체
DK0536275T3 (da) Tumorvækstinhibitorer udledt fra væv, fremgangsmåde til deres fremstilling samt anvendelse heraf
EP0909814A3 (en) Use of protein kinases for the diagnosis and treatment of Alzheimer's disease
US6489118B2 (en) Allergenic proteins and peptides from dog dander and uses therefor
Fraquelli et al. Gallbladder emptying and somatostatin and cholecystokinin plasma levels in celiac disease
EP1196450B1 (fr) Derives citrullines de la fibrine et leur utilisation pour le diagnostic ou le traitement de la polyarthrite rhumato de
DE69333076D1 (de) Test und behandlung von demyelinierenden krankheiten wie multiple sklerosis
SI0998556T1 (sl) Diagnoze in zdravljenje bolezni z uporabo anti-t-celičnih receptorjev vbeta antiteles ali peptidov, ki so prepoznani z omenjenimi antitelesi in protein 1 (esrp1) za uravnavo endokrinskih izločkov
EP0640101B1 (en) Methods and reagents for diagnosis of autoantibodies
RESETKOVA et al. Seroreactivity to bacterial antigens is not a unique phenomenon in patients with autoimmune thyroid diseases in Canada
BR0308095A (pt) Teste para anticorpos anti-ingap
WO1998042737A3 (en) Peptides for the treatment of systemic lupus erythematosus
BR9909308A (pt) Peptìdeo, ensaio para o diagnóstico de esquizofrenia em um indivìduo, e, kit para uso no diagnóstico de esquizofrenia
Tate et al. The ribosomal domain of the bacterial release factors.
Otley et al. The pathogenesis of dermatitis herpetiformis
Cusi et al. Peripheral neuropathy associated with anti-myelin basic protein antibodies in a woman vaccinated with rubella virus vaccine
CA2251058A1 (en) Diagnosis, prevention and treatment of ulcerative colitis, and clinical subtypes thereof, using histone h1
Adam et al. Rheumatoid arthritis and collagen antibodies
Szelényi et al. Immunomodulatory Effect and Acetylcholine Receptor Binding of a Thymopeptide (Tp4) on Human Peripheral Blood Lymphocytes
Jablonska Dermatomyositis
Veys et al. Review of immunotherapy in rheumatoid arthritis
SE8705197D0 (sv) New peptides, two diagnostic methods using the peptides and a medicament based on the peptides

Legal Events

Date Code Title Description
IF Valid on the event date